re: Ann: Pharmaxis Quarterly Investor Confere... trial duration is not the key issue for the sp decline from 12 to 7, its the continuous decline in sale from Germany and Australia is the problem, for 2 quarter, management didn't have answer.
however, worth to mention, their overall sales and gross profit is increasing, if they can contain overheads a bit further, sp might eventually climb.
Ann: Pharmaxis Quarterly Investor Conference Call, page-18
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.002(6.06%) |
Mkt cap ! $41.29M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.3¢ | 3.1¢ | $2.554K | 80.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 275331 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 189544 | 2 |
View Market Depth
| Last trade - 12.02pm 18/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |